Upcoming AMCP PIE Webinar
Beta Cell Preservation and Disease-Modifying Treatment for Autoimmune Type 1 Diabetes: Pre-Approval Information Exchange
Time: 2:00 PM to 3:00 PM ET
This product is indicated for use in stage 2 T1D patients aged 8 years and older to delay onset of stage 3 T1D. The data in this webinar regarding the use in stage 3 T1D patients is investigational and the safety and efficacy for this use has not been reviewed/approved by the US Food and Drug Administration (FDA).
This PIE webinar is sponsored by Sanofi. The content of the webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies.
Click below for webinar details and to register:
Archive
Past webinar topics
AMCP PIE Webinar: A Clinical Overview of Investigational Menin Inhibitor for the Treatment of NPM1-mutated R/R acute myeloid leukemia | Aug 28, 2025
Cencora | NASP Webinar: Breaking the Mold: What’s Next for Biosimilars and How to Stay Ahead | Aug 21, 2025
AMCP PIE Webinar: UGN-102 Pre-Approval Information Exchange (PIE) Presentationa | March 26, 2025
Cencora | NASP Webinar: Enhancing Specialty Drug Review and Formulary Insights | March 25, 2025
AMCP PIE Webinar: Investigational Cell-Based Autologous Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)a | March 4, 2025
AMCP PIE Webinar: Overview of clinical data for a potential treatment for PTSD in adults | December 5, 2024
AMCP PIE Webianr: Delgocitinib for the treatment of Chronic Hand Eczema (CHE) | November 20, 2024
AMCP PIE Webinar: Vutrisiran Preapproval Information Exchange Webinar | October 30, 2024
PIE webinars are sponsored. The content of the webinars and opinions expressed by the presenters and those of the sponsor or presenters and not of AMCP or FormularyDecisions. FormularyDecisions is proud to partner with AMCP to enable information sharing between healthcare decision-makers and biopharma companies. At the time of the webinar, the product was in the clinical evaluation stage and had not been approved for use by the FDA. The safety and efficacy had not been established.
